Publication:
New approach of the treatment of von Willebrand's disease during pregnancy.

Simple item page
dc.contributor.authorGojnic, Miroslava (9434266300)
dc.contributor.authorFazlagic, A. (23496293200)
dc.contributor.authorLikic, I. (23497909500)
dc.contributor.authorStefanovic, A. (8613866900)
dc.contributor.authorVidakovic, S. (9434348100)
dc.contributor.authorPervulov, M. (6602872337)
dc.contributor.authorPetkovic, S. (7005164142)
dc.contributor.authorMostic, T. (6506343126)
dc.contributor.authorMiljic, P. (6604038486)
dc.contributor.authorBogdanovic, A. (6603686934)
dc.date.accessioned2025-06-13T00:23:52Z
dc.date.available2025-06-13T00:23:52Z
dc.date.issued2005
dc.description.abstractAIM: The aim of the study was to analyze the effectiveness of the application of DDAVP (desmopressin) and Hemate P with cryoprecipitate pre- and postpartum in patients with von Willebrand disease. METHODS: We monitored 32 patients with von Willebrand disease during the study period 1993-2003. DDAVP was applied in the 36th/37th week of gestation and cryoprecipitate and fresh frozen plasma were applied 1 day before and 3 days after delivery. DDAVP treatment continued for 4 weeks. Factor VIII (Hemate P) at the day of delivery RESULTS: No complications occurred in the studied population. CONCLUSION: Precipitation of DDAVP, Hemate P, and cryoprecipitate may help in the treatment of pregnant women with von Willebrand disease.
dc.identifier.urihttps://doi.org/10.1007/s00404-005-0739-x
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-39049184899&doi=10.1007%2fs00404-005-0739-x&partnerID=40&md5=01f95f82c9182116dc637bd5b46d30e6
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/11034
dc.titleNew approach of the treatment of von Willebrand's disease during pregnancy.
dspace.entity.typePublication

Files

Collections

Publikacije / Publications